Rocket Pharmaceuticals (RCKT) Cash from Financing Activities (2014 - 2026)

Rocket Pharmaceuticals has disclosed Cash from Financing Activities across 13 years of filings, most recently posting -$1000.0 for Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at -$1000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $147000.0 (down 99.92% YoY), and the FY2025 annual result was $148000.0, down 99.92% from the prior year.
• Cash from Financing Activities came in at -$1000.0 for Q1 2026 at Rocket Pharmaceuticals, up from -$67000.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $189.5 million in Q3 2023 to a low of -$67000.0 in Q3 2025.
• The 5-year median for Cash from Financing Activities is $1.2 million (2024), against an average of $36.6 million.
• Across the five-year window, Cash from Financing Activities surged 46664.45% in 2024 and sank 138.07% in 2025, its largest moves.
• Rocket Pharmaceuticals' Cash from Financing Activities stood at $108.4 million in 2022, then tumbled by 99.64% to $391000.0 in 2023, then soared by 46664.45% to $182.8 million in 2024, then plunged by 100.04% to -$67000.0 in 2025, then jumped by 98.51% to -$1000.0 in 2026.
• The last three Cash from Financing Activities figures came in at -$1000.0 (Q1 2026), -$67000.0 (Q3 2025), and $215000.0 (Q2 2025), per Business Quant data.